Purpose: To evaluate changes in pancreatic cyst fluid DNA, frequency of cyst resolution, and complications following EUS-guided pancreas cyst ablation (EUS-PCA) with ethanol and paclitaxel (PTX). Methods: In a single center prospective study, consecutive patients with a 1-5 cm pancreatic cyst having ≤5 septations (irrespective of pancreatic duct [PD] communication) were considered. Exclusion criteria: active pancreatitis, necrosis, varices, ascites, coagulopathy, or dilated PD. Baseline evaluation: MRI or CT, EUS imaging and cyst fluid cytology, CEA and DNA analysis (PathFinderTG®, RedPath IP, Inc; Pittsburgh, PA). Initial cyst ablation using a 22G needle, EUS-guided lavage for 3-5 minutes with 100% ethanol then reaspirated and injected with an equal volume of 2 mg/mL paclitaxel, which was left in place. Three months later, repeat EUS for remnant cyst measurement, FNA of cyst fluid for cytology and DNA analysis with a second ablation if cyst size was ≥10 mm. This second ablation was considered on a case-by-case basis for patients with preceding ablation-induced pancreatitis. Three and 12 months later, pancreas protocol CT was performed. Baseline and post-ablation 3D volume CT or MRI images were interpreted by a single radiologist. Complete response (CR), partial response (PR), and a persistent cyst: CT or MRI with <5% of the original volume (OV), 5-25% of OV, and >25% of OV, respectively. Results: Twenty two patients (15 F; median 66 yrs) with cysts in the head (18), body (8), and tail (4) who initially refused or were ineligible for surgery were enrolled. EUS cyst morphology: median maximum diameter 25 mm (range:14-43), septated in eight (36%), and mural nodules in six (27%). Median cyst CEA: 315 ng/mL (range: 0.2-75508). Baseline cyst fluid DNA (n=22) had mutations in 11 (50%): Kras alone in five, Kras + 1 allelic loss [AL] in one, 2 ALs in two, and 1 AL in three. Clinical diagnoses: IPMN in 12, MCN in 6, and SCN 4. Initial ablation was done in all patients. Three had no follow up: one with single Kras who refused, one with single AL who had surgery, one without mutations who had post-treatment peritonitis. In the remaining 19, post-ablation EUS showed a median 77% decrease (range: -99.7 to 72.8) in cyst volume. Post ablation cyst fluid (n=19) showed elimination of all baseline mutations in eight, new ALs in three, and no changes in eight without a baseline mutation. Per protocol post-ablation CT volume (n=20): CR 10 (50%), PR (25%), persistent (25%). Complications for EUS-PCA (n=31): abdominal pain (23%), pancreatitis (10%), peritonitis (3%), gastric wall cyst (3%). Conclusion: In this series, EUS-PCA with ethanol and PTX may eliminate mutant DNA, lead to complete or partial CT resolution in 75% of cysts but result in potentially serious complications in 16% of injections. Disclosure: John DeWitt - Grant Support: PathFinderTG®, RedPath IP, Inc; Pittsburgh PA; Consultant: Boston Scientific, Cook Endoscopy; Julia LeBlanc - Speakers' Bureau, Cook Endoscopy. Stuart Sherman - Consultant, Boston Scientific, Cook Endoscopy Syd Finkelstein - Medical Director, RedPath Integrated Pathology. Mohammad Al-Haddad - Speaker's Bureau, Boston Scientific. This research was supported by an industry grant from RedPath IP, Inc; Pittsburgh PA.